Since the Vhl/Trp53/Rb1 mutant mouse ccRCC model does not generate metastases, it also does not allow investigation of the effects of immune checkpoint inhibitor therapy on metastatic disease, which may have a different immune microenvironment to the primary tumour. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.